Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 10;14:746. doi: 10.1038/s41467-023-36334-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Relative expression levels of POSTN isoforms in CCD-18Co treated with oxaliplatin. n = 4 and n = 3 biologically independent experiments for POSTNi4 and for POSTNi1-3, 5-8 respectively. Values are mean ± sd. p value is indicated. b Relative expression levels of POSTNi4 in CAFs treated with oxaliplatin. n = 3 biologically independent experiments. Values are mean ± sd. p values are indicated. c Relative expression levels of POSTNi4 in CCD-18Co treated with oxaliplatin w/o TGF-beta pathway inhibitor (TBRi). n = 3 biologically independent experiments. Values are mean ± sd. p values are indicated. d Relative expression levels of POSTNi4 in CCD-18Co 6, 12, 90, 180 days after oxaliplatin retrieval. n = 3 biologically independent experiments. Values are mean ± sd. p value is indicated. e POSTN protein levels in genetically engineered PDOs with upregulated expression of POSTNi4 compared to control cells. Bottom panel shows β-Actin protein levels as normalization control. Representative of n = 3 biologically independent experiments. f Growth kinetics upon oxaliplatin treatment of tumors derived from subcutaneous injection into NSG mice of PDOs-Ct or POSTNi4-secreting PDOs. Left panel: PDOs-Ct injected mice tumors treated (red; n = 10) or non-treated tumors (blue; n = 9). Right panel: POSTNi4-PDOs injected mice tumors treated with oxaliplatin (red; n = 9) or non-treated tumors (blue; n = 7). Values are mean ± sem. p values are indicated. PDO patient-derived tumor organoids, Fib CCD-18Co, Ct control, Ox oxaliplatin. Two-sided, unpaired t-test p values (p) are indicated for a–d, f. Source data are provided as a Source Data file.